Soviets See Market Forces As Salvation For Science In Post-Perestroika Period

LENINGRAD--Dimitry Filotov is an unlikely scientific pioneer. The 30-year-old physicist, who wears a windbreaker and blue jeans in his lab and sports a shaggy head of hair, is not a member of the Soviet Academy of Sciences, the prestigious organization that dominates the country's scientific enterprise through its network of some 350,000 scientists and technicians at about 500 research institutes. Nor does he drive a Mercedes Benz, the Soviet Union's most visible status symbol. In fact, at the

Written byFred Guterl
| 12 min read

Register for free to listen to this article
Listen with Speechify
0:00
12:00
Share

Filotov, however, belongs to an elite group of Soviet scientists who are riding high on a new wave of applied research. His future prosperity is linked closely to efforts in the Soviet Union to realign the country's massive research enterprise along the lines of a market economy. This effort could lead to greater opportunities for collaboration with Western scientists, as well as cooperative ventures with Western companies.

Alexander Golubok has the right idea at the right time. But the Soviet researcher is in the wrong place to develop his technology. Golubok's lab at the Science and Technology Corporation has developed a scanning tunneling microscope with analytical software and other features that Golubok claims are superior to Western products. However, the microscope will not function unless it is hooked up to a wardrobe-sized rack of electronics and cables. Since the corporation lacks the capability to fabricate the integrated circuits needed to ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Meet the Author

Published In

Share
Image of a man in a laboratory looking frustrated with his failed experiment.
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies